Gene · 64115
Papers2,513
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 2,513
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PD-1H (VISTA) Expression in Cutaneous Squamous Cell Carcinoma Is Correlated with T-Cell Infiltration and Activation. | J Invest Dermatol | 2025 | 39983979 | PubTator, text mining | PubMed |
| Intracellular and extracellular activities of V-domain Ig-containing suppressor of T cell activation (VISTA) modulated by immunosuppressive factors of tumour microenvironment. | Cancer Lett | 2025 | 39983894 | PubTator, text mining | PubMed |
| Prognostic Stratification of Epithelioid Pleural Mesothelioma Based on the Hippo-TEADs Network. | Cancers (Basel) | 2025 | 39941836 | PubTator, text mining | PubMed |
| Advancements in immunotherapy for gastric cancer: Unveiling the potential of immune checkpoint inhibitors and emerging strategies. | Biochim Biophys Acta Rev Cancer | 2025 | 39938663 | PubTator, text mining | PubMed |
| Targeting cell-surface VISTA expression on allospecific naïve T cells promotes tolerance. | Blood | 2025 | 39919264 | PubTator, text mining | PubMed |
| Artificial metabzyme-driven metabolic reprogramming and precision oncology. | Clin Transl Med | 2025 | 39888283 | PubTator, text mining | PubMed |
| YAP/TEAD4/SP1-induced VISTA expression as a tumor cell-intrinsic mechanism of immunosuppression in colorectal cancer. | Cell Death Differ | 2025 | 39875519 | PubTator, text mining | PubMed |
| Expression and correlation analysis of VISTA in peripheral blood mononuclear cells of myasthenia gravis patients. | Int Immunopharmacol | 2025 | 39862630 | PubTator, text mining | PubMed |
| Correction: A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy. | Biomark Res | 2025 | 39849601 | PubTator, text mining | PubMed |
| Metabolically activated and highly polyfunctional intratumoral VISTA+ regulatory B cells are associated with tumor recurrence in early-stage NSCLC. | Mol Cancer | 2025 | 39810191 | PubTator, text mining | PubMed |
| Mismatch prime editing gRNA increased efficiency and reduced indels. | Nat Commun | 2025 | 39747083 | PubTator, text mining | PubMed |
| FOXO1 pathway activation by VISTA immune checkpoint restrains pulmonary ILC2 functions. | J Clin Invest | 2025 | 39745792 | PubTator, text mining | PubMed |
| Novel PD-L1/VISTA Dual Inhibitor as Potential Immunotherapy Agents. | J Med Chem | 2025 | 39731560 | PubTator, text mining | PubMed |
| Immunotherapeutic strategies beyond the PD-1/PD-L1 pathway in head and neck squamous cell carcinoma - A scoping review on current developments in agents targeting TIM-3, TIGIT, LAG-3, and VISTA. | Oral Oncol | 2025 | 39705929 | PubTator, text mining | PubMed |
| Small molecule inhibitors targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for cancer immunotherapy (2020-2024). | Eur J Med Chem | 2025 | 39653621 | PubTator, text mining | PubMed |
| V-domain immunoglobulin suppressor of T-cell activation and programmed death receptor 1 dual checkpoint blockade enhances antitumour immunity and survival in glioblastoma. | Br J Pharmacol | 2025 | 39626657 | PubTator, text mining | PubMed |
| Feedback regulation of VISTA and Treg by TNF-α controls T cell responses in drug allergy. | Allergy | 2025 | 39526799 | PubTator, text mining | PubMed |
| VSIG-3/IGSF11 silencing in A2058 melanoma cells simultaneously suppresses melanoma progression and induces anti-tumoral cytokine profile in human T cells: In silico and in vitro study. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | 39365310 | PubTator, text mining | PubMed |
| Comparison of PD-L1, VISTA, LAG-3, and GAL-3 Expressions and Their Relationships to Mismatch Repair Protein and p53 Expression in 529 Cases of Endometrial Carcinoma. | Int J Gynecol Pathol | 2025 | 38914021 | PubTator, text mining | PubMed |
| Bioinformatics screening of prognostic immune-related genes in renal clear cell carcinoma. | J Appl Genet | 2025 | 38780866 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64115/papers?page=10